NASDAQ:CVKD
Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. reported net income of −$13.2M in fiscal 2025. Free cash flow was −$12.6M, and the diluted share count rose 63.5%.Summary generated from Cadrenal Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 31, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−260.1%
Debt / equityn/a
Free cash flow−$12.6M
FCF marginn/a
Share count change+63.5%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | n/a | n/a | n/a |
| Operating income | −8 | −11 | −13 |
| Net income | −8 | −11 | −13 |
| Free cash flow | −4 | −7 | −13 |
Recent filings
- 8-KRegulation FD disclosure
Oct 7, 2026 - 8-KDirector or officer change
Sep 29, 2026 - 8-KRegulation FD disclosure
Aug 31, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - DEF 14AProxy statement
Aug 3, 2026 - 8-KRegulation FD disclosure
Jul 21, 2026 - 8-KDirector or officer change
Jul 17, 2026